PROJECT44
project44 , the global leader in advanced visibility for shippers and logistics service providers, today announced a new formal certification to award a seal of approval to the top performing over-the-road carriers in Europe. Online training and tools to prepare for a certification process will be available late May. The company initiated the global certification process for their over-the-road carrier network in April this year.
Built as the industry's connective tissue, project44 provides instant access to the most expansive and highest performing multimodal global network. This includes connections to more than 760 telematics providers, representing 94% of the European market, and connections to 2.4 million drivers and 2 million trucks in Europe. Approximately 5000 European truckload carriers are consistently tracking over 90% compliance. To achieve best in class performance metrics, project44 has implemented extensive best practices guidelines and educational programming with over the road carrier groups as well as telematics providers.
“Coop operates with more than 1,000 stores who all need deliveries on a weekly basis. For us to have the most efficient supply chain, we lacked an end-to-end overview of our carrier and subcontractor deliveries,” said Kennet Thorsen, Senior Distribution Manager of Coop Denmark A/S. “Our organization leveraged project44’s robust carrier network and world-class onboarding process to rapidly increase the ROI of our technology investment, streamline operations and better meet service goals towards our stores.”
Since its initial launch in 2017, the NMC has provided carriers with instant access to over 300 global retailers, manufacturers, distributors, and logistics service providers, representing $57B of managed freight. While providing the opportunity for new business and revenue growth, project44 helps carriers increase their operating efficiencies and streamline the data sharing process.
“Strong technology and quality data are essential for our success,” said Kristian Kaas Mortensen, Director of Strategic Partnerships at Girteka Logistics, a Europe's leading asset-based transport company that delivers over 730,000 full truck loads annually.
Mortensen added, “We could never fulfill our mission with yesterday’s technology — that’s why all our trucks and our subcontractors’ trucks are connected to project44. Visibility and collaboration between us, our customers and our subcontractors are key in today’s world.”
“An extensive and high-performing carrier network and global multimodal optionality are critical at all times,” said Tommy Barnes, Head of Global Network Partnerships at project44. “By investing into the depth, breadth, and quality of our network, we continue delivering on our commitment to end-to-end visibility and frictionless collaboration that increase efficiency and profitability for the entire transportation ecosystem.”
Learn more or schedule a demo today.
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. project44 received the 2020 SAP® Pinnacle Award as the Cloud Partner Integration of the Year. To learn more, visit www.project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005007/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom